Format
Items per page
Sort by

Send to:

Choose Destination

Results: 18

Related Articles by Review for PubMed (Select 15310763)

1.

Orexins acting at native OX(1) receptor in colon cancer and neuroblastoma cells or at recombinant OX(1) receptor suppress cell growth by inducing apoptosis.

Rouet-Benzineb P, Rouyer-Fessard C, Jarry A, Avondo V, Pouzet C, Yanagisawa M, Laboisse C, Laburthe M, Voisin T.

J Biol Chem. 2004 Oct 29;279(44):45875-86. Epub 2004 Aug 13.

2.

The orexin receptor OX(1)R in colon cancer: a promising therapeutic target and a new paradigm in G protein-coupled receptor signalling through ITIMs.

Laburthe M, Voisin T.

Br J Pharmacol. 2012 Mar;165(6):1678-87. doi: 10.1111/j.1476-5381.2011.01510.x. Review.

3.

The physiology and pharmacology of the orexins.

Smart D, Jerman J.

Pharmacol Ther. 2002 Apr-May;94(1-2):51-61. Review.

PMID:
12191593
4.

Orexins/hypocretins: pain regulation and cellular actions.

Chiou LC, Lee HJ, Ho YC, Chen SP, Liao YY, Ma CH, Fan PC, Fuh JL, Wang SJ.

Curr Pharm Des. 2010;16(28):3089-100. Review.

PMID:
20687883
5.

Orexins (hypocretins) and adrenal function.

Jöhren O, Brüggemann N, Dominiak P.

Horm Metab Res. 2004 Jun;36(6):370-5. Review.

PMID:
15241726
6.

Orexins and their receptors: structural aspects and role in peripheral tissues.

Voisin T, Rouet-Benzineb P, Reuter N, Laburthe M.

Cell Mol Life Sci. 2003 Jan;60(1):72-87. Review.

PMID:
12613659
7.

[Orexins and pain processing].

Yamamoto T, Shono K.

Masui. 2007 Jan;56(1):40-7. Review. Japanese.

PMID:
17243644
8.

Orexins in the regulation of the hypothalamic-pituitary-adrenal axis.

Spinazzi R, Andreis PG, Rossi GP, Nussdorfer GG.

Pharmacol Rev. 2006 Mar;58(1):46-57. Review.

9.

Interactions of orexins/hypocretins with adrenocortical functions.

Kagerer SM, Jöhren O.

Acta Physiol (Oxf). 2010 Mar;198(3):361-71. doi: 10.1111/j.1748-1716.2009.02034.x. Epub 2009 Aug 28. Review.

PMID:
19719797
10.

Central and local (enteric) action of orexins.

Korczynski W, Ceregrzyn M, Matyjek R, Kato I, Kuwahara A, Wolinski J, Zabielski R.

J Physiol Pharmacol. 2006 Nov;57 Suppl 6:17-42. Review.

11.

[Central action of orexins on sympathetic outflow and cardiovascular function with a focus on the paraventricular nucleus of the hypothalamus].

Kannan H, Shirasaka T, Watanabe S, Yu NS, Kuitake T, Takasaki M.

Masui. 2007 Jan;56(1):30-9. Review. Japanese.

PMID:
17243643
12.

Orexins and the regulation of the hypothalamic-pituitary-testicular axis.

Nurmio M, Tena-Sempere M, Toppari J.

Acta Physiol (Oxf). 2010 Mar;198(3):349-54. doi: 10.1111/j.1748-1716.2009.02006.x. Epub 2009 May 20. Review.

PMID:
19476455
13.

Drugs to interfere with orexins (hypocretins).

Selbach O, Eriksson KS, Haas HL.

Drug News Perspect. 2003 Dec;16(10):669-81. Review.

PMID:
14747847
14.

Physiology of the orexinergic/hypocretinergic system: a revisit in 2012.

Kukkonen JP.

Am J Physiol Cell Physiol. 2013 Jan 1;304(1):C2-32. doi: 10.1152/ajpcell.00227.2012. Epub 2012 Oct 3. Review.

15.

Apoptosis-independent functions of killer caspases.

Algeciras-Schimnich A, Barnhart BC, Peter ME.

Curr Opin Cell Biol. 2002 Dec;14(6):721-6. Review.

PMID:
12473345
16.

Vineyard peptide conference bears fruit.

Hagan RM, McLean S.

Trends Pharmacol Sci. 1993 Sep;14(9):315-8. Review. No abstract available.

PMID:
8249150
17.

The orexins: linking circulatory control with behavior.

Ehmke H, Just A.

Am J Physiol Regul Integr Comp Physiol. 2003 Sep;285(3):R519-21. Review. No abstract available.

18.

The effect of neuropeptides on cellular proliferation.

Pawlikowski M.

Mater Med Pol. 1987 Jan-Mar;19(1):17-20. Review. No abstract available.

PMID:
3329268
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk